维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="DIASIO R B"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics显示文摘	Mattison L K Soong R Diasio R B	2002	Pharmacogenomics2002，3，4：	1
2	Comparative pharma- cokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluraeil in patients with advanced solid tumors 显示文摘	ADJEI A A REID J M DIASIO R B	2002	J Clin Oncol2002，20，6：	1
3	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer 显示文摘	MEROPOL N J GOLD P J DIASIO R B	2006	J Clin Oncol2006，24，25：	1
4	Thymidine phos- phorylase expression is associated with response to eapecitabineplus irinotecan in patients with metastatic colorectal cancer显示文摘	MEROPOL N J GOLD P J DIASIO R B	2006	J Clin Oncol2006，24，25：	1
5	Histone deacetylase inhibitors: current status and overview of recent clinical trials 显示文摘	MA X EZZELDIN H H DIASIO R B	2009	Drugs2009，69，14：	1
6	The role of pharmacogenetics and pharmacogenomlcs in cancer chemotherapy with 5-fluorouracll 显示文摘	Diasio R B Johnson M R	2000	Pharmacology2000，61，3：	1
7	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer显示文摘	MEROPOL N J COLD P J DIASIO R B er al	2006	V Clin Oncol2006，24，25：	1
8	The role of pharmacogenetics and pharmacogcnomics in cancer chemotherapy with 5- fluorouracil 显示文摘	Diasio R B Johnson M R	2000	Pharmacology2000，61，3：	1
9	Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype显示文摘	JOHNSON M R WANG K DIASIO R B	2002	Clin Cancer Res2002，8，3：	1
10	Edotecarin: a novel topoisomerase I inhibitor 显示文摘	Saif M W Diasio R B	2005	Clin Colorectal Cancer2005，5，1：	1
11	Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines显示文摘	Diasio R B	1999	Drugs1999，58，3：	1
12	Genetic resting in cancer therapeutics显示文摘	Ezzeldin H H Diasio R B	2006	Clin Cancer Res2006，12，：	1
13	Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygotegenotype显示文摘	JOHNSONNG K Diasio R B	2002	ClinCancerRes2002，8，3：	1
14	Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy显示文摘	DIASIO R B LU Z	1994	J Clin Oncol1994，12，11：	1
15	Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype 显示文摘	JOHNSON M R WANG K DIASIO R B	2002	Clin Cancer Res2002，8，3：	1
16	Clinical implications of dihydropyrimidine dehydrogenase inhibition显示文摘	Diasio R B	1999	Oncoloy (Williston Park)1999，13，3：	1
17	Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy 显示文摘	LU Z ZHANG R DIASIO R B	1993	Cancer Res1993，53，22：	1
18	Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy显示文摘	DIASIO R B LU Z	1994	J Clin Oncol1994，12，11：	1
19	Clinical pharmacology of 5-Fluorouracil显示文摘	DIASIO R B HARRIS B E	1989	Clin Pharmacokinet1989，16，4：	1
20	Clinical pharmacology of 5- fluorouracil 显示文摘	Diasio R B Harris B E	1989	Clinical Pharmacokinetics1989，16，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示